Mendus AB (publ) (OM: IMMU)
Health Care · Biotechnology · SE
Skr6.85
-0.72% today · -8.5% 1Y
Mendus AB (publ) (OM: IMMU) operates in the Biotechnology industry within the Health Care sector. The company is valued at $46.10M and employs 27 people.
Over the last twelve months the share price has lost 8.5%, trading between 3.86 and 9.37.
Tweenvest scores Mendus AB (publ) across four factors: quality 36/100. Its strongest factor is quality.
IMMU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.10M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.77
- Dividend yield
- —
- Beta (5Y)
- 0.75
- 52-week high
- Skr9.37
- 52-week low
- Skr3.86
- Avg volume (3M)
- —
- Shares outstanding
- 63.73M
- Employees
- 27
- Next earnings
- —
About Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
- ISIN
- SE0022239950
- Founded
- 2002
- Listed since
- Apr 22, 2013
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.